UNITED
STATES


SECURITIES
AND EXCHANGE COMMISSION


Washington,
D.C. 20549




FORM
8-K





CURRENT
REPORT


Pursuant
to Section 13 or 15(d) of The Securities Exchange Act of 1934




Date of
Report (Date of earliest event reported)September 14,
2009




Progenics
Pharmaceuticals, Inc.


(Exact
name of registrant as specified in its charter)




Delaware
            
            000-23143
            
            13-3379479(State
      or other jurisdiction
              of
      incorporation)
            
            (Commission
              File
      Number)
            
            (IRS
      Employer
              Identification
      No.)777
      Old Saw Mill River Road, Tarrytown, New York
            
            10591(Address
      of principal executive offices)
            
            (Zip
      Code)Registrant's telephone number,
      including area code(914)
      789-2800




Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (seeGeneral
Instruction A.2. below):






oWritten communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)




oSoliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)




oPre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))




oPre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))









Item
5.02 Departure of Directors or Certain Officers; Election of Directors;
Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.





On
September 14, 2009, the Board of Directors of Progenics Pharmaceuticals, Inc.
(Nasdaq: PGNX) elected Mark R. Baker President of the Company and a member of
its Board of Directors, increasing the number of directors of the Company to
nine.  Mr. Baker, formerly the Company’s Executive Vice President –
Corporate, General Counsel and Secretary, will retain the latter titles and
continue to report to Paul J. Maddon, M.D., Ph.D., the Company’s Founder, Chief
Executive Officer and Chief Science Officer.  Mr. Baker will serve as
a director, subject to his earlier resignation or removal, until the Company’s
2010 annual meeting of stockholders and the election and qualification of his
successor.  He will not receive any additional compensation for
service as a director.  Additional information concerning Mr. Baker
contained in the Company’s Proxy Statement for its Annual Meeting of
Stockholders held on June 8, 2009 is incorporated herein by reference
thereto.





The
Company’s press release announcing Mr. Baker’s election as President and a
director is attached as Exhibit 99.1, and the information contained therein is
incorporated by reference into this Item 5.02 of this Current Report on Form
8-K.





Item
9.01   Financial Statements and Exhibits.




(d)
Exhibits





Exhibit
No.     Description




99.1
            Press
      Release dated September 16, 2009.








SIGNATURES






Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.




PROGENICS
PHARMACEUTICALS, INC.


By:/s/ ROBERT A.
MCKINNEY


Robert A. McKinney


Chief Financial Officer, Senior
Vice President,


Finance & Operations and
Treasurer








Date:  September
16, 2009